SCHEMBL16635714

SCHEMBL16635714

O=C(O)C1CCC(F)(F)CC1C(=O)Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A12 P48065 1/20 0.40
SLC6A11 P48066 1/20 0.40
POLB P06746 1/20 0.34
TSHR P16473 1/20 0.34
KCNQ3 O43525 3/20 0.34
KCNQ2 O43526 3/20 0.34
KCNQ4 P56696 2/20 0.34
KCNQ5 Q9NR82 2/20 0.34
GRM4 Q14833 4/20 0.32
CYP2C19 P33261 2/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
GRM8 O00222 1/20 0.32
GRM6 O15303 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
GABRR1 P24046 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9450418 0.90 KCNQ3 (0.33) SLC6A12SLC6A11KCNQ3KCNQ2KCNQ4
SCHEMBL10704175 0.88 SLC6A12 (0.45) SLC6A12SLC6A11POLBTSHRKCNQ3
SCHEMBL16636028 0.80 SLC6A12 (0.37) SLC6A12SLC6A11POLBTSHRKCNQ3
SCHEMBL17803111 0.78 SLC6A12 (0.41) SLC6A12SLC6A11POLBTSHRKCNQ3
SCHEMBL19756870 0.78 SLC6A12 (0.41) SLC6A12SLC6A11POLBTSHRKCNQ3
SCHEMBL17814235 0.78 SLC6A12 (0.41) SLC6A12SLC6A11POLBTSHRKCNQ3
SCHEMBL16617896 0.77 KCNQ3 (0.37) SLC6A12SLC6A11POLBTSHRKCNQ3
SCHEMBL16637758 0.77 KCNQ3 (0.37) SLC6A12SLC6A11POLBTSHRKCNQ3
SCHEMBL16636353 0.76 HRH3 (0.32) KCNQ3KCNQ2KCNQ4KCNQ5MEN1
SCHEMBL16636351 0.76 HRH3 (0.32) KCNQ3KCNQ2KCNQ4KCNQ5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015051479-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ SLC6A12 3618/4885SLC6A11 4205/4885POLB 3196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.